DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Dalcetrapib is an investigational drug.
There have been 14 clinical trials for Dalcetrapib. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2015.
The most common disease conditions in clinical trials are Coronary Disease, Coronary Artery Disease, and Myocardial Ischemia. The leading clinical trial sponsors are Hoffmann-La Roche, DalCor Pharmaceuticals, and The Montreal Health Innovations Coordinating Center (MHICC).
There are one hundred and fifty-seven US patents protecting this investigational drug and two international patents.
Recent Clinical Trials for Dalcetrapib
|Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19||Covance||Phase 2|
|Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19||The Montreal Health Innovations Coordinating Center (MHICC)||Phase 2|
|Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19||DalCor Pharmaceuticals||Phase 2|
Top disease conditions for Dalcetrapib
Top clinical trial sponsors for Dalcetrapib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Dalcetrapib||Start Trial||Pharmaceutical compositions with enhanced performance and improved processability||HERCULES LLC (Wilmington, DE)||Start Trial|
|Dalcetrapib||Start Trial||Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent||Hoffmann-La Roche Inc. (Little Falls, NJ)||Start Trial|
|Dalcetrapib||Start Trial||CETP activity inhibitors||Japan Tobacco Inc. (Tokyo, JP)||Start Trial|
|Dalcetrapib||Start Trial||Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals||Aventis Pharma Deutschland GmbH (Frankfurt am Main, DE)||Start Trial|
|Dalcetrapib||Start Trial||CETP activity inhibitor||Japan Tobacco Inc. (Tokyo, JP)||Start Trial|
|Dalcetrapib||Start Trial||Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals||Aventis Pharma Deutschland GmbH (Frankfurt Am Main, DE)||Start Trial|
|Dalcetrapib||Start Trial||Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors||Pfizer Inc. (New York, NY)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Dalcetrapib||European Patent Office||EP2961775||2033-03-01||Start Trial|
|Dalcetrapib||South Korea||KR20150125655||2033-03-01||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|